Chiesi Farmaceutici Sustainability Profile
Chiesi Farmaceutici, a prominent player in the global pharmaceutical industry, is headquartered in Parma, Italy. Founded in 1935, the company has established a strong presence in various operational regions, including Europe, North America, and Asia. Specialising in innovative treatments for respiratory diseases, neonatology, and rare diseases, Chiesi is renowned for its commitment to research and development, which has led to several key milestones in the biopharmaceutical sector. The company’s core products, including advanced inhalation therapies and specialty medicines, are distinguished by their focus on patient-centric solutions. Chiesi Farmaceutici has garnered recognition for its sustainable practices and dedication to improving health outcomes, positioning itself as a leader in the pharmaceutical market. With a rich history and a forward-thinking approach, Chiesi continues to make significant contributions to healthcare worldwide.
DitchCarbon Score
How does Chiesi Farmaceutici's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Chiesi Farmaceutici's score of 82 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Chiesi Farmaceutici's reported carbon emissions
In 2024, Chiesi Farmaceutici reported total carbon emissions of approximately 1,022,663,000 kg CO2e, with Scope 1 emissions at about 24,653,000 kg CO2e, Scope 2 emissions at approximately 49,600 kg CO2e (market-based) and 12,822,000 kg CO2e (location-based), and Scope 3 emissions reaching about 997,514,000 kg CO2e. This represents an increase from 2023, where total emissions were approximately 980,116,000 kg CO2e, with Scope 1 at about 29,906,000 kg CO2e, Scope 2 at approximately 591,000 kg CO2e (market-based) and 12,254,000 kg CO2e (location-based), and Scope 3 at about 949,619,000 kg CO2e. Chiesi has set ambitious climate commitments, aiming to achieve a 50% reduction in absolute Scope 1 and Scope 2 emissions by 2030, using 2019 as the baseline year. Additionally, they target a 90% reduction in absolute Scope 3 emissions from the use of sold products by 2035. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to net-zero greenhouse gas emissions across all scopes by 2035. The company has made significant strides in reducing its emissions, with a reported 12% decrease in Scope 1 emissions and a 96% reduction in Scope 2 market-based emissions compared to the 2019 baseline. Chiesi's sustainability strategy includes a focus on renewable energy sources, with 99% of electricity consumption coming from renewables at most sites. Overall, Chiesi Farmaceutici's climate commitments and emissions data demonstrate a proactive approach to sustainability within the pharmaceutical industry, aiming for substantial reductions in greenhouse gas emissions while contributing to global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 18,840,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,872,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Chiesi Farmaceutici's Industry?
How Carbon Intensive is Chiesi Farmaceutici's Location?
Chiesi Farmaceutici's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Chiesi Farmaceutici has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Chiesi Farmaceutici's sustainability data and climate commitments